Articles tagged with Fibrosis
Rentosertib, a breakthrough drug candidate for idiopathic pulmonary fibrosis (IPF), has been granted an official generic name by the USAN Council. The drug's development was accelerated using generative AI, identifying TNIK as a promising target and designing small-molecule compounds in just 18 months.
The collaboration aims to close gaps in early recognition and management of IPF by equipping healthcare providers, public health professionals, and patients with necessary resources. The organizations will employ designated activities to build a knowledge base, develop survey tools, and create educational and awareness assets.
SLC transporters contribute to the development of hepatic steatosis by regulating lipid metabolism, particularly with SLC2A2, GLUT4, and GLUT5. These proteins influence processes like de novo lipogenesis and insulin resistance in hepatocytes.
This disorder has diverse etiologies, variable presentations, and different therapeutic responses. The proposed diagnostic algorithm can differentiate pediatric MF subtypes to improve patient outcomes.
A collaborative study reveals two distinct types of scarring, referred to as “hot” and “cold,” which require entirely different treatments for diseased hearts. The researchers found that hot fibrosis is driven by an immune response, while cold fibrosis is a self-maintaining process.
Scientists have pinpointed two proteins in immune cells that, when blocked, can significantly reduce lung tissue scarring and restore regeneration. Blocking YAP and TAZ can curb scar formation by dampening inflammation, maintaining a healthy immune cell ratio, and disrupting their communication with nearby cells.
Researchers at TUM found that cystic fibrosis causes changes in the immune system as early as birth, leading to frequent inflammation and infections. These changes are not affected by CFTR modulator therapies.
A USF study found that patients with pulmonary fibrosis who contracted severe COVID-19 experienced lung improvement. Researchers are exploring factors associated with this finding to develop new treatments, including applying knowledge gained from COVID-19 patients to idiopathic pulmonary fibrosis patients. The study suggests a possibl...
A new approach to cancer therapy is being developed by inhibiting mechanotransduction, a process that regulates processes such as tumour progression and wound healing. The INTROPY project aims to validate the potential of six molecules in blocking this process, offering a new strategy for cancer treatment.
Researchers discovered that removing arginase-II gene can slow down muscle aging in mice, leading to improved muscle health and reduced inflammation. This finding suggests targeting the Arg-II gene could help maintain muscle strength and mobility in older adults.
Researchers reveal senescence's impact on liver health, from repair and regeneration to chronic disease progression. Emerging therapies, such as senolytic treatments, aim to selectively eliminate senescent cells while preserving healthy tissue.
Researchers found that previously thought 'pro-fibrotic' macrophages are not solely responsible for fibrosis and instead may contribute to healthy repair. The study aims to understand the triggers behind these differences in expression, with the goal of harnessing macrophages for lung repair.
Researchers have discovered that AHCC suppresses liver fibrosis by inhibiting the activation of hepatic stellate cells through two channels. Early administration of AHCC may hold the key to preventing the onset of cirrhosis, a potentially fatal condition.
Researchers have discovered that dextromethorphan, an FDA-approved ingredient found in many cough syrups, has potential to treat fibrotic lung disease. The study, published in Science Translational Medicine, showed how dextromethorphan can impede collagen formation, reducing lung scarring and stiffness.
Researchers discovered a novel combination of plasma-based biomarkers that can predict liver fibrosis in Latino adolescents with obesity. The study found that dihydroxyacetone phosphate (DHAP) and alanine transaminase (ALT) were significantly associated with fibrosis, suggesting a potential low-cost, noninvasive screening tool.
A new study published in Lancet Gastroenterology and Hepatology found that a combined screening approach can detect liver damage in people with type 2 diabetes. The method involves elastography, an ultrasound-based technique, which was found to be willing to be adopted by most patients. Early detection of liver fibrosis is crucial, as ...
Longidaza significantly reduced exertional desaturation and dyspnea, as well as improved distance walked during the six-minute walk test. The drug's effects on exercise tolerance were sustained for over 100 days after treatment.
A new study finds that a blood test using phosphatidylethanol (PEth) can detect liver disease caused by excessive drinking, offering a more reliable alternative to self-reported measures. The test has shown strong correlation with Fibrosis 4, an indicator of liver risk, and could be included in routine blood tests.
GLP-1RAs improve liver histology, reduce liver fat, and enhance metabolic parameters in MASLD patients. However, challenges remain in assessing long-term liver benefits and clarifying the effects on liver fibrosis.
Researchers identified plasma extracellular vesicle-derived microRNAs as potential biomarkers for AATD liver disease. They found 39 differentially expressed miRNAs, which were validated in an independent cohort for predicting AATD liver disease.
Researchers have identified a simpler and more accessible alternative to diagnosing kidney fibrosis in transplant patients: measuring vitronectin levels in urine. The study found that vitronectin levels were significantly higher in patients with fibrosis, and combining this measurement with traditional urine tests improved accuracy.
The Phase IIa trial of ISM001-055 showed dose-dependent improvement in forced vital capacity (FVC) and percent predicted FVC, suggesting potential to slow or reverse disease progression. The treatment also demonstrated a favorable pharmacokinetics profile with minimal adverse events.
Experimental mouse models are crucial for studying liver fibrosis regression, with various models exhibiting reversible fibrosis after removal of causative agents or therapeutic interventions. However, challenges persist in replicating human disease progression and regression, highlighting the need for further refinement of these models.
A cohort study reveals that AATD patients with COPD have a unique liver transcriptomic profile, with upregulated pathways related to fibrosis and inflammation. Histopathological analysis confirms higher levels of fibrosis and hepatocellular damage in these individuals.
A U.S.-based single-center retrospective cohort study found that advanced liver fibrosis is a primary risk factor for incident liver decompensation and liver-related events in patients with biopsy-proven metabolic dysfunction-associated steatotic liver disease. The study, published in the Journal of Clinical and Translational Hepatolog...
Gladstone researchers have identified a complex molecular connection between immune cells and fibroblasts that contributes to fibrosis in the heart, which may lead to new treatments for heart disease and other fibrotic conditions.
Researchers identified CYP1B1 as a biomarker for HSC activation and liver fibrosis in patients and mice. Inhibition of CYP1B1 led to the accumulation of trehalose, which has anti-fibrotic activity, protecting mice from liver fibrosis.
Researchers confirm that fibrosis in HER2-negative breast tumors is associated with an adverse prognosis and better treatment outcomes with nintedanib. A new test, MeCo Score, analyzes gene activity related to fibrosis and indicates the effectiveness of supplementing chemotherapy with antifibrotic therapy.
Researchers at the University of Barcelona have identified a potential new strategy to slow the development of liver fibrosis. Activating the PPARβ/δ-AMPK pathway has been found to prevent collagen accumulation and reduce inflammation in the liver, according to a study published in Biomedicine & Pharmacotherapy.
Researchers discovered a novel treatment that extends ovarian function in older mice by improving maintenance of the ovaries and preventing key age-related changes. The treatment also fixes hormone production and overall health, alleviating symptoms such as bone loss, cardiovascular disease, and cognitive decline.
Researchers identified protein kinase N as a key regulator of heart fibrosis, which threatens heart function. Deleting this enzyme reduced cardiac dysfunction, suggesting anti-PKN treatments may protect against heart failure.
A new study found that cystic fibrosis patients with more severe disease characteristics exhibit shorter leukocyte telomere length and greater LTL attrition. This association may accelerate aging and increase susceptibility to age-related diseases, emphasizing the importance of early CF diagnosis and timely therapeutic intervention.
A literature review examines key cell-cell interactions driving pulmonary fibrosis, revealing complex interplay between diverse lung cell types and intricate processes. The study highlights potential ligands involved in PF, including tumor necrosis factor, interleukin 1β, and ADAM17, and suggests targeting CCIs for novel therapies.
Researchers have identified key cellular interactions and microenvironments that contribute to the development of chronic kidney disease (CKD) after acute kidney injury (AKI) in mice. The study, published in Nature Communications, provides new insights into how damaged cells interact within disease-promoting microenvironments.
Researchers discovered faulty immune processes responsible for lingering lung issues after COVID-19, which can be disrupted by existing drugs. The study also identified molecules responsible for the issue and potential therapeutic options for patients with ongoing lung damage.
Researchers at Tokyo Medical and Dental University discovered the role of A20 in suppressing chronic hepatitis by inhibiting the DCLK1-JNK pathway-dependent chemokines. In mice lacking A20 expression, hepatic stellate cells displayed spontaneous inflammation and increased chemokine levels.
Researchers discovered a parasite protein that enhances wound healing in mice by stimulating immune cells to promote tissue regeneration and inhibit scarring. The protein, TGM, accelerates wound closure and improves skin regeneration.
Researchers at Sanford Burnham Prebys discovered that specific macrophage subpopulations, including TREM2+, are critical for resolving MASH and liver fibrosis. These cells help reduce inflammation, slow disease progression, and promote healing.
Researchers at the University of Virginia School of Engineering and Applied Science have designed a drug-carrying molecule that can slip past the lung's natural defenses. The nanocarrier, called PEG-BB, is shaped like a bottlebrush and mimics the properties of mucus, allowing it to move quickly through the airway.
A new study by Korea University College of Medicine shows that direct-acting antivirals significantly reduce liver-related clinical outcomes and lower the risk of disease progression to cancer or cirrhosis, increasing life expectancy for patients with Hepatitis C. The treatment approach has a high effectiveness rate of 90%.
Researchers have developed a suite of parameters that can be used to quantitatively measure different physical characteristics of the lung. The parameters were found to be highly sensitive and specific for diagnosing fibrosis and edema in an animal model, using only five necessary parameters.
Researchers at UCLA Health found that reducing inflammation may not influence the extent of liver fibrosis in MAFLD. The study suggests that other pathways could be more effective in targeting fibrosis and improving outcomes for patients.
A research group developed a long-acting artificial hepatocyte growth factor (HGF) mimetic molecule using cyclic peptides and protein engineering. The molecule improved liver fibrosis, lipid accumulation, and inflammation in a mouse model with non-alcoholic steatohepatitis (NASH), providing an option for NASH therapeutics.
Research reveals the critical role of epigenetic regulation in hepatic stellate cell activation and liver fibrogenesis. Key findings include DNA methylation, histone modifications, and non-coding RNAs modulating HSC activation, with potential therapeutic implications for NAFLD.
A new compound developed by researchers at MUSC Hollings Cancer Center has shown promise in improving response to chemotherapy in preclinical models. The compound inhibits the protein lysyl oxidase, preventing it from producing a stiff environment around tumors and allowing drugs to penetrate better.
These disorders, including CHF, CD, CS, ALGS, and BA, result from genetic mutations affecting bile formation and transport. Management focuses on symptom control, prevention of complications, and definitive treatment with liver transplantation when indicated.
Researchers created a new cell model to study the effects of senescence on lung fibroblasts. Senescent alveolar epithelial cells triggered fibrotic activation in lung fibroblasts, which was attenuated by senolytic therapy.
Scientists have identified a critical genetic mechanism driving cardiac fibrosis and found a novel target for its reversal. The discovery sheds light on the role of transforming growth factor-beta (TGFβ) and ATP-citrate lyase (ACLY) in promoting excessive tissue scarring, providing hope for new heart failure treatments.
Researchers found increased liver oxidative stress and impaired antioxidant defenses in a DS murine model. The study suggests potential therapeutic strategies targeting oxidative stress and lipid metabolism to prevent or mitigate liver-related complications.
Researchers from Aarhus University have developed a method that can detect the earliest changes in the kidney when scar tissue begins to form. This technology uses hyperpolarized 13C-pyruvate MRI to track fibrosis formation, allowing doctors to start treatment earlier and potentially prevent damage.
A team of researchers has discovered a mechanism by which the liver's immune cells are suppressed in chronic hepatitis B, leading to organ damage. The 'sleep timer' function allows immune cells to weaken their activity over time, preventing them from proliferating excessively and causing further damage.
Researchers at Chiba University have discovered a new mechanism of ILC2 immune cell development, which may exacerbate allergic diseases. The study found that the induction of GATA3 expression by an ILC2-specific super-enhancer is essential for ILC2 differentiation.
A large-scale study confirms the rising incidence of eosinophilic esophagitis (EoE) in Japan, with a significant increase in cases between 2005 and 2022. The study found an incidence rate of 2.82 per 100,000 person-years and a prevalence rate of 10.68 per 100,000 people.
FM0807 reduces blood glucose levels, improves liver function, and decreases kidney damage in diabetic mice. The compound also inhibits inflammatory markers and alters SMAD2/3 expression, suggesting a protective role in regulating JAK2/STAT3 and TGF-β1/SMAD2/3 signaling pathways.
Researchers found that pentraxin 3 is a non-invasive biomarker for severe fibrosis and increased carotid intima-media thickness in patients with MAFLD. Elevated PTX3 levels were associated with advanced fibrosis and larger CIMT values.
Researchers created an integrated cellular map of a mouse model heart, pinpointing cells and pathways involved in fibrosis. The study identified myofibroblasts as the major drivers of scarring, but also discovered a 'matrifibrocyte' form that may prevent scar resolution.
This study found that TIMP-1 induces the expression of transcription factor Fli-1, which elevates MCP-1 expression and promotes hepatic macrophage recruitment. siRNA-TIMP-1 alleviated liver fibrosis by reducing macrophage migration and MCP-1 expression.
Researchers have developed a novel patch that can help liver tissue regenerate and inhibit inflammation. The patch demonstrated restored liver function in lab tests and promoted recovery from liver fibrosis in rats, showing great potential for treating liver diseases.
A new study has found that FAPI PET/CT is more effective than FDG in predicting progressive pulmonary fibrosis in ILD patients. The study's results suggest that FAPI PET/CT can identify high-risk patients who require closer monitoring or preventive treatment.
Researchers at UTEP have developed a new therapeutic approach to treat skin and lung fibrosis by targeting and rehabilitating cells responsible for the disease. The nanoparticles successfully modified the cells to stop producing excess collagen, offering hope for improved treatments and enhanced quality of life.